Nucleoside compounds for treating viral infections

A compound selected from the group consisting of:

• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-monophospho-β-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphospho-β-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-triphospho-β-D-ribofuranosyl)-4-amino-5-(ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-monophospho-β-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphospho-β-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-triphospho-β-D-ribofuranosyl)-4-amino-5-(2-cis-methoxy-ethen-1-yl)-pyrrolo[2,3-d]pyrimidine;
• or pharmaceutically acceptable salts or partial salts thereof.

A compound of formula II:

• wherein
• Y is selected from the group consisting of a bond, —CH2— or —O—;
• each of W, W1 and W2 is independently selected from the group consisting of hydrogen and a pharmaceutically acceptable prodrug;
• and
• or pharmaceutically acceptable salts or partial salts thereof.

A compound selected from the group consisting of:

• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-phospho-β-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphospho-β-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• and
• 7-(2′-C-methyl-5′-triphospho-β-D-ribofuranosyl)-4-amino-5-(2-carboxyethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• or pharmaceutically acceptable salts or partial salts thereof.

A compound of formula III:

• wherein
• Y is selected from the group consisting of a bond, —CH2— or —O—;
• R2 is alkyl;
• each of W, W1 and W2 is independently selected from the group consisting of hydrogen and a pharmaceutically acceptable prodrug;
• and
• or pharmaceutically acceptable salts or partial salts thereof.

A compound selected from the group consisting of:

• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-phospho-β-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-phospho-β-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphospho-β-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphospho-β-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-triphospho-β-D-ribofuranosyl)-4-amino-5-[(ethyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• and
• 7-(2′-C-methyl-5′-triphospho-β-D-ribofuranosyl)-4-amino-5-[(methyl 2-carboxyl)ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• or pharmaceutically acceptable salts or partial salts thereof.

A compound of formula IV:

• wherein
• Y is selected from the group consisting of a bond, —CH2— or —O—;
• each of W, W1 and W2 is independently selected from the group consisting of hydrogen and a pharmaceutically acceptable prodrug;
• and
• or pharmaceutically acceptable salts or partial salts thereof.

A compound selected from the group consisting of:

• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-(ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-phospho-β-D-ribofuranosyl)-4-amino-5-(ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphospho-β-D-ribofuranosyl)-4-amino-5-[ethyn-1-yl]-pyrrolo[2,3-d]pyrimidine;
• and
• 7-(2′-C-methyl-5′-triphospho-β-D-ribofuranosyl)-4-amino-5-(ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• or pharmaceutically acceptable salts or partial salts thereof.

A compound of formula V:

• wherein
• Y is selected from the group consisting of a bond, —CH2— or —O—;
• each of W, W1 and W2 is independently selected from the group consisting of hydrogen and a pharmaceutically acceptable prodrug;
• R20 is selected from the group consisting of hydrogen, carboxyl, carboxyl esters, phenyl, and phenyl substituted with from 1 to 2 substitutents selected from the group consisting of methyl, ethyl, and halo;
• and
• p is 0, 1, or 2;
• or pharmaceutically acceptable salts or partial salts thereof.

A compound selected from the group consisting of:

• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-β-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-phospho-β-D-ribofuranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-phospho-β-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-phospho-β-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphospho-β-D-ribofuranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphospho-β-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-diphosphol-β-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-triphosphol-β-D-ribofaranosyl)-4-amino-5-(2-phenylethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• 7-(2′-C-methyl-5′-triphosphol-β-D-ribofuranosyl)-4-amino-5-(2-(4-fluorophenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• and
• 7-(2′-C-methyl-5′-triphosphol-β-D-ribofuranosyl)-4-amino-5-(2-(4-methylphenyl)ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine;
• or pharmaceutically acceptable salts or partial salts thereof.